Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: A pilot study

Cynthia Marie-Claire (1) , Cindie Courtin (1) , Emmanuel Curis (1, 2, 3) , Elodie Bouaziz-Amar (1, 4) , Jean-Louis Laplanche (1, 4) , Aude Jacob (1) , Bruno Etain (1, 5, 6) , Anne Blanchard (7) , Frank Bellivier (1, 5, 6)

1 VariaPsy - U1144 - Variabilité de réponse aux Psychotropes
2 BioSTM - EA 7537 - Biostatistique, traitement et modélisation des données biologiques
3 AP-HP, GH Saint-Louis – Lariboisière – F. Widal, Département de biostatistiques et d'informatique médicales, Paris, France
4 GH Saint-Louis – Lariboisière – F. Widal, Département de Biochimie et Biologie moléculaire, Paris, France
5 AP-HP, GH Saint-Louis – Lariboisière – F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris Cedex 10, France
6 Fondation FondaMental [Créteil]
7 UPD5 Médecine - Université Paris Descartes - Faculté de Médecine

High mobility group box 1 (HMGB1) is a pro-inflammatory cytokine that emerges as a promising peripheral marker of inflammation. HMGB1 and C-reactive protein levels were assessed in plasma of control subjects and remitted patients with bipolar disorder (BD). HMGB1 levels were significantly higher in patients with BD as compared to control subjects whereas C-reactive protein levels did not differ between the two groups. No significant effect of potential covariates was identified. The results of this pilot study suggest that HMGB1 might be a specific peripheral marker of inflammation in BD.

Mots clés: Bipolar disorder; HMGB1; Inflammation; Plasma

Domaines: Génomique, Transcriptomique et Protéomique [q-bio.GN]; Psychiatrie et santé mentale; Génétique humaine

Cynthia Marie-Claire, Cindie Courtin, Emmanuel Curis, Elodie Bouaziz-Amar, Jean-Louis Laplanche, et al.. Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: A pilot study. Journal of Neuroimmunology, 2019, 334, pp.576993. ⟨10.1016/j.jneuroim.2019.576993⟩. ⟨hal-02335130⟩